{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:00Z","timestamp":1792008060984,"version":"4.4.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cld.2023.05.005","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:55:49Z","timestamp":1688086549000},"page":"809-818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?"],"prefix":"10.1016","volume":"27","author":[{"given":"Jonggi","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Mook","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2023.05.005_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2023.05.005_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib3","doi-asserted-by":"crossref","first-page":"e165033","DOI":"10.1172\/JCI165033","article-title":"Liver-resident CD8+ T\u00a0cells in viral hepatitis: not always good guys","volume":"133","author":"Luxenburger","year":"2023","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cld.2023.05.005_bib4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2018.12.001","article-title":"The trends in incidence of primary liver cancer caused by specific etiologies: results from the global burden of disease study 2016 and implications for liver cancer prevention","volume":"70","author":"Liu","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib6","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/S1590-8658(10)60507-5","article-title":"The changing pattern of epidemiology in hepatocellular carcinoma","volume":"42","author":"Nordenstedt","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2023.05.005_bib7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.005_bib8","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib9","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2023.05.005_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib11","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.005_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3350\/cmh.2019.1002","article-title":"KASL clinical practice guidelines for management of chronic hepatitis B","volume":"25","author":"Korean Association for the Study of the","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib13","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.26686","article-title":"No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B","volume":"59","author":"Kitrinos","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.005_bib14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.005_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01064-18","article-title":"No resistance to tenofovir alafenamide detected through 96\u00a0weeks of treatment in patients with chronic hepatitis B infection","volume":"62","author":"Cathcart","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2023.05.005_bib16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib19","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1128\/AAC.00833-06","article-title":"Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present","volume":"51","author":"Tenney","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2023.05.005_bib20","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.005_bib21","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2023.05.005_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jvh.12613","article-title":"No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment","volume":"24","author":"Liu","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2023.05.005_bib23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2014-308353","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.05.005_bib24","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/gutjnl-2014-308435","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.05.005_bib25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/hep.29187","article-title":"Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial","volume":"66","author":"Lim","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.005_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jhep.2019.02.021","article-title":"Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: a 5-year clinical trial","volume":"71","author":"Lim","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","article-title":"Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate","volume":"20","author":"Byun","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2022.12.016","article-title":"Tenofovir alafenamide for multiple drug-resistant chronic hepatitis B: a 3-year clinical trial","author":"Choi","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cld.2023.05.005_bib31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2018.05.009","article-title":"Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B","volume":"69","author":"Wong","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.14309\/ajg.0000000000000490","article-title":"Earlier alanine aminotransferase normalization during antiviral treatment is independently associated with lower risk of hepatocellular carcinoma in chronic hepatitis B","volume":"115","author":"Choi","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2023.05.005_bib33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/apt.16788","article-title":"Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data","volume":"55","author":"Lim","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2023.05.005_bib34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV : a cohort study","volume":"174","author":"Surial","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2023.05.005_bib35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/apt.17107","article-title":"Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study","volume":"56","author":"Ogawa","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2023.05.005_bib36","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1177\/2047487319862401","article-title":"Total cholesterol\/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: the ARIC study","volume":"27","author":"Quispe","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cld.2023.05.005_bib37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3350\/cmh.2022.0028","article-title":"Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles","volume":"28","author":"Lin","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib38","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3350\/cmh.2021.0314","article-title":"Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis","volume":"28","author":"Jeong","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAI.0000000000001350","article-title":"Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E\/C\/F) for Initial HIV-1 treatment: week 144 results","volume":"75","author":"Arribas","year":"2017","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cld.2023.05.005_bib40","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/hep.29321","article-title":"Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population","volume":"66","author":"Choi","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.005_bib41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1053\/j.gastro.2014.02.033","article-title":"Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine","volume":"147","author":"Lim","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.05.005_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","article-title":"Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries","volume":"18","author":"Hou","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.05.005_bib44","doi-asserted-by":"crossref","first-page":"13537","DOI":"10.1038\/s41598-020-70433-z","article-title":"Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate","volume":"10","author":"Ha","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cld.2023.05.005_bib45","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","article-title":"A\u00a0multicenter study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in South Korea","volume":"71","author":"Kim","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib46","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","article-title":"Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis","volume":"69","author":"Lee","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.05.005_bib47","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2020.06.011","article-title":"Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B","volume":"73","author":"Papatheodoridis","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","article-title":"Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis","volume":"19","author":"Choi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.31267","article-title":"Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-Analysis","volume":"73","author":"Dave","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.005_bib50","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1097\/MCG.0000000000001548","article-title":"Differential effectiveness of tenofovir and entecavir for prophylaxis of hepatocellular carcinoma in chronic hepatitis B patients depending on coexisting cirrhosis and prior exposure to antiviral therapy: a systematic review and meta-analysis","volume":"55","author":"Jeong","year":"2021","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cld.2023.05.005_bib51","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1136\/gutjnl-2019-320326","article-title":"Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis","volume":"69","author":"Teng","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.05.005_bib52","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000507253","article-title":"Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.cld.2023.05.005_bib53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12072-019-10005-0","article-title":"Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis","volume":"14","author":"Li","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2023.05.005_bib54","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/jgh.15036","article-title":"Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis","volume":"35","author":"Gu","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib55","doi-asserted-by":"crossref","first-page":"e00236","DOI":"10.14309\/ctg.0000000000000236","article-title":"Entecavir vs tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis","volume":"11","author":"Cheung","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cld.2023.05.005_bib56","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s12885-019-5735-9","article-title":"The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cld.2023.05.005_bib57","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib58","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jhep.2021.09.017","article-title":"Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments","volume":"76","author":"Choi","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib59","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jhep.2022.12.007","article-title":"Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: individual patient data meta-analysis","volume":"78","author":"Choi","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib60","unstructured":"Lim Y, Chan HLY, Seto W, et\u00a0al. Impact of treatment with Tenofovir Alafenamide (Taf) or Tenofovir Disoproxil fumarate (Tdf) on hepatocellular carcinoma (Hcc) incidence in patients with chronic hepatitis B (Chb), In The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2019, John Wiley & Sons, Inc. The Journal's web site is located at http:\/\/www\u2026, 2019."},{"key":"10.1016\/j.cld.2023.05.005_bib61","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/liv.15261","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive chronic hepatitis B","volume":"42","author":"Lim","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2023.05.005_bib62","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/jvh.13601","article-title":"Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B","volume":"28","author":"Lee","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2023.05.005_bib63","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.31289","article-title":"Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection","volume":"73","author":"Choi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.005_bib64","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Imamura","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.005_bib65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/gast.2000.9373","article-title":"Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma","volume":"119","author":"Chen","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.05.005_bib66","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000518940","article-title":"Tenofovir is superior to entecavir on tertiary prevention for BCLC Stage 0\/A hepatocellular carcinoma after curative resection","volume":"11","author":"Tsai","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.cld.2023.05.005_bib67","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1002\/cam4.4348","article-title":"Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: a multicenter study","volume":"10","author":"Qi","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.cld.2023.05.005_bib68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejim.2021.02.019","article-title":"The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma","volume":"89","author":"Lee","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cld.2023.05.005_bib69","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00535-022-01855-x","article-title":"Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection","volume":"57","author":"Wang","year":"2022","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cld.2023.05.005_bib70","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jvh.13766","article-title":"Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: a systematic review and meta-analysis","volume":"30","author":"Giri","year":"2023","journal-title":"J\u00a0Viral Hepat"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612300065X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612300065X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:00:56Z","timestamp":1761069656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108932612300065X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S108932612300065X"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.005","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}